Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AFP Imaging receives license to market ENT scanner in Canada
The NewTom VG provides clinicians with detailed three-dimensional, radiographic images of the teeth and jaws while allowing patients to stand, sit, or remain in their wheel chairs while
The NewTom VG provides clinicians with detailed three-dimensional, radiographic images of the teeth and jaws while allowing patients to stand, sit, or remain in their wheel chairs while
The acquisition will support Hansen Medical leveraging its Sensei Robotic Catheter system, which is currently marketed for electrophysiology procedures, into the rapidly developing market for percutaneous heart valve
Under the terms of the agreement, Pfizer will make a cash tender offer for all of the outstanding common stock of Coley for $8 per share, representing an
Under the terms of the merger agreement, Celgene will acquire all of the outstanding shares of Pharmion common stock for $72 per share payable in a combination of
Regulatory T cells are a specialized subpopulation of T cells that actively control immune system responses and prevent immune-mediated diseases. Regulatory T cells can be isolated from a
As assessed by independent radiological review, 36% of glioblastoma multiforme (GBM) patients treated with Avastin alone, and 51% of patients treated with Avastin in combination with chemotherapy, lived
The study was designed to confirm the positive results from the European clinical study program, which led to a pan-European registration of the tablet in 2006. The study
The new drug application (NDA) is supported by data from two Phase III clinical studies (AIR-CF1 and AIR-CF2) and interim data from an ongoing open-label extension study (AIR-CF3)
Marlyn Nutraceuticals has been ordered by the US District Court to immediately stop using the Wobenzym trademark and selling products under this name. Wobenzym was initially developed by
This study evaluated stool-based DNA (sDNA) in 82 patients with colorectal cancer and 363 colonoscopically normal individuals using Exact’s version 2 technology. The study results were statistically consistent